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Abstract
Background: The coiled-coil coactivator (CoCoA) enhances transcriptional activity of nuclear
receptors, the xenobiotic aryl hydrocarbon receptor, and the lymphocyte enhancer factors (LEF)
in the Wnt/β-catenin signaling pathway. CoCoA is comprised of a large central coiled coil domain
flanked by N-terminal and C-terminal activation domains (AD). The N-terminal AD of CoCoA is
required for coactivator function with LEF and β-catenin, while the C-terminal AD of CoCoA is
required for coactivator function with nuclear receptors. We explored the role of sumoylation in
regulating the activities of the two ADs and the coactivator function of CoCoA.
Results: The N-terminus of CoCoA is covalently modified by SUMO1 at Lys-29; both PIAS1 and
ARIP3 function as E3 ligases. Fusion of SUMO1 to the N-terminus (mimicking sumoylation) reduced
coactivator function of CoCoA with LEF1 and the activity of the N-terminal AD. The N- and C-
termini of CoCoA can bind to each other, and C-terminal transactivation activity is attenuated in
the presence of the N-terminus, indicating that the N-C interaction regulates the activity of the C-
terminal AD. Fusion of SUMO1 to the N-terminal fragment of CoCoA reduced the N-C
interaction and inhibition of C-terminal AD activity by the N-terminal fragment.
Conclusion: Sumoylation of CoCoA differentially regulates the coactivator activity of CoCoA
with nuclear receptors versus LEF1, by attenuating the N-terminal AD activity and enhancing the
activity of the C-terminal AD.
Background
Post-translational modification of proteins is a widely
used mechanism for regulation of a variety of cellular
processes. Modification by the ubiquitin homologue, the
small ubiquitin-like modifier 1 (SUMO1, also known as
sentrin, GMP1, UBL1, and PIC1) [1], has been identified
as an essential mechanism for the dynamic regulation of
gene expression, cell cycle progression, DNA repair, and
cellular protein trafficking [2,3]. There are three mamma-
lian SUMOs, SUMO1, SUMO2 and SUMO3. SUMO1
consists of 101 amino acids, and shares approximately
50% sequence identity with SUMO2 and SUMO3, and
with the yeast Smt 3 protein [4]. Ligation of SUMO1 to
specific lysine residues of target proteins is a multi-step
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process which resembles ubiquitin conjugation. SUMO1
is initially made as an inactive precursor which matures by
an ATP-dependent carboxy-terminal proteolytic cleavage
event, catalyzed by the E1 activation enzyme complex
containing the UBA2 and AOS1 proteins. Activated
SUMO1 is subsequently attached covalently to the E2
conjugating enzyme Ubc9, and finally conjugated to the
ε-amino group of specific lysine residues of target proteins
by an E3 ligase. While there is only one known E2 conju-
gating enzyme, many E3 ligases for sumoylation have
been identified. These include the polycomb protein Pc2
[5], RanBP2 [6], and members of the PIAS family, which
includes PIAS1, PIAS3, PIASy, PIASxα/ARIP3, PIASxβ/
Miz3 and hZimp10 [7,8]. In addition to their E3 ligase
acitivity, PIAS1 has been shown to activate transcription
factors such as p53 by a mechanism independent of ligase
activity [9].
The physiological effects of protein sumoylation are
extremely varied. Sumoylation is involved in cytokine sig-
naling by attenuating the activity of the activated forms of
STAT1, which is responsible for inducing the expression
of specific genes in response to cytokines [10,11].
Sumoylation of the PIASy protein, which subsequently
promotes sumoylation of lymphocyte enhancer factor 1
(LEF1) in the developmentally important Wnt/β-catenin
signaling pathway, results in sequestration of LEF1 to the
PML nuclear bodies and inhibition of LEF1-mediated
transcription [12]. Sumoylation of a number of nuclear
receptors has also been demonstrated and generally
results in inhibition of these transcriptional activators
[13-15].
In this study, we focus on the functional significance of
sumoylation of the coiled-coil coactivator (CoCoA).
Although CoCoA was originally discovered as a coactiva-
tor for nuclear receptors [16] and the aryl hydrocarbon
receptor [17], it is also involved in the transcriptional acti-
vation of target genes by LEF/T cell factor (TCF) transcrip-
tion factors, some of which are controlled by the Wnt/β-
catenin pathway [18]. Wnt ligands lead to stabilization
and increased cellular levels of β-catenin, which enters the
nucleus and binds to and serves as a coactivator for LEF/
TCF transcription factors [19]. LEF/TCF transcription fac-
tors bind to specific DNA sequences which serve as
enhancer elements controlling the expression of specific
genes. DNA-bound LEF/TCF recruits the coactivator β-cat-
enin, which functions as a scaffold for binding of other
coactivators, including CBP/p300, p160 coactivators, pro-
tein arginine methyltransferase CARM1, and CoCoA [20].
CoCoA consists of a large central coiled-coil domain,
flanked by N-terminal and C-terminal activation domains
(ADs). Both the N-terminal and C-terminal ADs of
CoCoA interact with the C-terminal region of β-catenin.
The N-terminal AD of CoCoA is necessary and sufficient
to bind to and cooperate with β-catenin as a coactivator
for LEF/TCF proteins in transient transfection assays; the
C-terminal AD of CoCoA is not required [20]. In contrast,
when CoCoA functions as a coactivator for nuclear recep-
tors, the functional domain requirements are completely
different. Hormone activated nuclear receptors bind spe-
cific DNA enhancer elements and recruit p160 coactiva-
tors, which serve as scaffolds for binding of a variety of
coactivators, including CBP/p300, CARM1, and CoCoA
[21]. The coiled-coil domain of CoCoA binds to the N-ter-
minal region of the p160 coactivator; the C-terminal AD
of CoCoA, but not the N-terminal AD, is required for the
coactivator function of CoCoA with nuclear receptors
[16,18]. The mechanisms of action of each AD of CoCoA
are unique and complex, but one common element of
their activity involves the binding of CBP/p300 to a spe-
cific amino acid motif that occurs in both ADs [20,22].
Because CoCoA uses different activation domains in its
coactivator functions with nuclear receptors and LEF1, dif-
ferential regulation of the relative activities of the N-termi-
nal and C-terminal ADs of CoCoA could differentially
modulate the ability of CoCoA to enhance the function of
LEF/TCF transcription factors versus nuclear receptors.
Here we report that CoCoA is SUMO-modified in vitro and
in vivo. Sumoylation of CoCoA is stimulated by the SUMO
E3 ligases PIAS1 and ARIP3. Mutation of the major
sumoylation site of CoCoA or fusion of SUMO1 to the N-
terminus of CoCoA (mimicking the natural sumoylation
process) altered the activity of CoCoA N-terminal AD and
the coactivator function of CoCoA. Interestingly, while
wild type CoCoA N-terminal AD can bind to and repress
the activity of the CoCoA C-terminal AD, the SUMO1
fusion to CoCoA N-terminus attenuated the interaction.
Taken together, our data suggest that sumoylation of
CoCoA regulates the differential use of the ADs by attenu-
ating the N-terminal AD activity and by enhancing the
activity of the CoCoA C-terminal AD. Thus, sumoylation
may favor CoCoA coactivator function with nuclear recep-
tors versus LEF1/β-catenin.
Results
Sumoylation of CoCoA in vivo and in vitro
Many transcription factors and cofactors have been iden-
tified as sumoylation targets. We therefore examined the
possibility of post-transcriptional modification of CoCoA
by SUMO1 conjugation. Inspection of the amino acid
sequence of CoCoA for the sumoylation concensus
sequence ψKxD/E (where ψ is any hydrophobic amino
acid and x is any amino acid) revealed several putative
sumoylation sites at the N-terminus and at the C-terminal
end of the coiled-coil domain (Fig. 1A). We next tested
whether CoCoA can be covalently modified by SUMO1.
COS-7 cells were transiently transfected with HA-taggedBMC Molecular Biology 2008, 9:12 http://www.biomedcentral.com/1471-2199/9/12
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CoCoA and SUMO1 fused to enhanced green fluorescent
protein (EGFP). Immunoblot analysis of the cell extracts
with anti-HA antibody revealed a major ~100 kDa band
corresponding to the unmodified full-length CoCoA and
a less intense, more slowly migrating band when full-
length CoCoA was co-expressed with EGFP-SUMO1 (Fig.
1B). This slow migrating band was not observed when
CoCoA was expressed without EGFP-SUMO1. A slow
migrating band was also observed when the N-terminal
fragment of CoCoA (amino acids 1–190) was expressed
with EGFP-SUMO1, but not in the absence of EGFP-
SUMO1. In contrast, no additional slow-moving band
Sumoylation of CoCoA Figure 1
Sumoylation of CoCoA. (A) Schematic diagram of predicted sumoylation sites of CoCoA. AD, activation domain; LZ, leu-
cine zipper-like sequence. (B) In vivo sumoylation of CoCoA. COS-7 cells were transfected with pSG5.HA.ARNT, 
pSG5.HA.CoCoA full-length, or pSG5.HA.CoCoA deletion mutants (800 ng); an EGFP-SUMO1 expression vector (200 ng) 
was co-transfected, where indicated. Cell extracts were collected 48 h post-transfection and analyzed by immunoblot with 
anti-HA antibody. Arrowheads indicate apparent sumoylation products. (C) In vitro sumoylation of CoCoA. In vitro translated 
35S-labeled CoCoA(1–190) was incubated with purified sumoylation E1 (Aos1/Uba2 heterodimer) and E2 (Ubc9) enzymes in 
the presence of ATP/Mg2+ and SUMO1. In the mock reaction, the CoCoA was omitted. Products were analyzed by SDS-PAGE 
and autoradiography.BMC Molecular Biology 2008, 9:12 http://www.biomedcentral.com/1471-2199/9/12
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was observed when the coiled-coil region (amino acids
150–500) or the C-terminus (amino acids 470–691) of
CoCoA was co-expressed with EGFP-SUMO1. The ARNT
protein, which is a confirmed sumoylation target [23],
also generated a slow migrating band when co-expressed
with EGFP-SUMO1 and thus served as a positive control
for this in vivo sumoylation assay (Fig. 1B). When the 35S-
labeled N-terminal fragment of CoCoA (amino acids
1–190) was produced by in vitro translation and incu-
bated in a cell free sumoylation reaction, slow-migrating
bands were observed, as expected for sumoylated CoCoA
N-terminal fragment (Fig. 1C). These results suggest that
CoCoA is modified by SUMO1 in vitro and in vivo within
the N-terminal region. It is clear from the data that only a
small fraction of CoCoA is sumoylated at any given time.
Enhancement of CoCoA sumoylation by PIAS1 and ARIP3
A number of proteins have been identified as SUMO E3
ligases; when over-expressed, these proteins can enhance
the degree of substrate sumoylation in cells. We tested two
known E3 ligases, PIAS1 and ARIP3/PIASxα, which are
known to enhance sumoylation of other transcription
coactivators, including the p160 coactivator GRIP1 [24].
As shown above (Fig. 1B), co-expression of full-length
CoCoA or the N-terminal fragment of CoCoA with EGFP-
SUMO1 produced a faint, slow-migrating species (Fig. 2,
lanes 2 and 6). Over-expression of PIAS1 or ARIP3 sub-
stantially enhanced the amount of the higher molecular
weight CoCoA species (lanes 3, 4, 7, and 8), suggesting
that PIAS1 and ARIP3 can act as E3 ligases for sumoyla-
tion of CoCoA. Furthermore, co-immunoprecipitation
assays showed that CoCoA interacts with PIAS1 in vivo
(data not shown). The enhanced intensity of the high
molecular weight bands in the presence of known E3
ligases also confirms that these higher molecular weight
bands are indeed SUMO-conjugated forms of CoCoA.
Identification of the sumoylation site in CoCoA
Sumoylation occurs at lysine residues within a specific
sequence context. CoCoA contains a number of putative
sumoylation sites (Fig. 1A). However, only two of the
putative sites are located in the N-terminal region (amino
acids 1–190) which was shown above (Figs. 1 and 2) to
undergo sumoylation in vivo. Of these two predicted
sumoylation sites, the sequence around Lys-52 (FKVE)
perfectly matches the accepted consensus sumoylation
sequence, while the sequence around Lys-29 (TKVE) par-
tially matches the consensus sequence. We tested whether
mutation of either Lys-29 or Lys-52 to arginine (K29R and
K52R) would affect the sumoylation status of CoCoA. In
immunoblot analyses of extracts from COS-7 cells
expressing wild type or mutant CoCoA (full length), the
sumoylation of the K29R mutant of CoCoA was dramati-
cally reduced, compared with wild type CoCoA; however,
in multiple experiments a very weak band was still
observed at the correct position for sumoylated CoCoA
(Fig. 3A). However, mutation of K52R, which lies in a per-
fect sumolyation consensus sequence, caused little or no
reduction in the sumoylation of CoCoA. Double muta-
tion at both K29 and K52 further reduced or eliminated
the sumoylated CoCoA species. In the N-terminal frag-
ment of CoCoA (amino acids 1–190) the K29R mutation
caused a similar reduction in sumoylation (Fig. 3B). These
results indicate that K29 is the major site of sumoylation
in CoCoA, while K52 may be a minor sumoylation site.
We next tested whether CoCoA can be modified by
SUMO2. As shown in Fig. 3C, CoCoA was efficiently con-
jugated to SUMO2. Mutation at K29 also abolished
CoCoA sumoylation by SUMO2. These results confirmed
that K29 is the major sumoylation site of CoCoA.
Effect of sumoylation on the function of CoCoA N-
terminal AD
Sumoylation has been found to regulate protein function
in a variety of ways, including effects on cellular localiza-
tion, protein-protein interactions, and transcriptional
activation activity. Mammalian two-hybrid and co-immu-
noprecipitation assays failed to detect any difference in
the ability of wild-type CoCoA and the K29R mutant of
CoCoA to homo-dimerize or interact with GRIP1 (data
not shown). In addition, no difference in the cellular dis-
tribution of wild-type and K29R mutant CoCoA was
PIAS1 and ARIP3 act as SUMO E3 ligases for CoCoA Figure 2
PIAS1 and ARIP3 act as SUMO E3 ligases for CoCoA. 
COS-7 cells were co-transfected with plasmids expressing 
HA-CoCoA or HA-CoCoA(1–190) (800 ng), EGFP-SUMO1 
(200 ng), and PIAS1 or ARIP3 (100 ng) as indicated. Cell 
extracts were collected 48 h post-transfection and analyzed 
by immunoblot with anti-HA antibody. Arrowheads indicate 
the SUMO-conjugated CoCoA or CoCoA(1–190).BMC Molecular Biology 2008, 9:12 http://www.biomedcentral.com/1471-2199/9/12
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Identification of SUMO1 conjugation site in CoCoA Figure 3
Identification of SUMO1 conjugation site in CoCoA. (A) COS-7 cells were co-transfected with plasmids expressing 
EGFP-SUMO1 (200 ng), PIAS1 (100 ng), and full-length HA-CoCoA wild type or mutants (800 ng) as indicated. (B) 293T cells 
were transfected with plasmids expressing EGFP-SUMO1 (200 ng), PIAS1 (100 ng), and HA-CoCoA(1–190) wild type or K29R 
mutant (800 ng) as indicated. Cell extracts were collected 48 h after transfection and analyzed by immunoblot with anti-HA 
antibody. (C) COS-7 cells were co-transfected with plasmids expressing Myc-SUMO2 (200 ng), PIAS1 (100 ng), and full-length 
HA-CoCoA wild type or mutants (800 ng) as indicated. Cell extracts were collected 48 h after transfection and analyzed by 
immunoblot with anti-HA antibody.BMC Molecular Biology 2008, 9:12 http://www.biomedcentral.com/1471-2199/9/12
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observed by confocal microscopy (data not shown). How-
ever, when the wild type or mutant CoCoA N-terminal AD
fragment was fused to GAL4 DNA binding domain
(DBD), the K29R mutant displayed a moderately
increased autonomous activation function compared to
the wild type AD fragment (Fig. 4A, assays 3–7). Similar
quantities of the wild type and mutant expression vectors
produced different amounts of CoCoA protein. When the
activities of similar amounts of wild type and mutant pro-
teins were compared, the mutant protein was moderately
more active (e.g. assay 4 versus 5 and 6).
Previously we have shown that CoCoA functions as a sec-
ondary coactivator for LEF1. LEF1, bound to its specific
enhancer element, recruits β-catenin, which serves as a
molecular scaffold for recruitment of various secondary
coactivators, such as CBP/p300, CARM1, and CoCoA
[18]. The N-terminal AD of CoCoA is important for this
coactivator function with LEF1/β-catenin for two reasons:
it contains a binding site for β-catenin and it also contains
the AD function which contributes to the overall process
of transcriptional activation [20]. Surprisingly, deletion of
the C-terminal AD did not compromise the ability of
CoCoA to cooperate with β-catenin as a coactivator for
LEF1, and even the N-terminal fragment (amino acids
1–190) alone cooperated with β-catenin as a coactivator
for LEF1. Although we do not know the complete mecha-
nism by which the CoCoA N-terminal domain helps to
promote formation of an active RNA polymerase II com-
plex on the promoter, we have shown that one important
element of the N-terminal AD is a binding motif for the
KIX domain of p300 located at amino acids 17–24 of
CoCoA. Point mutations in this motif of CoCoA disrupt
p300 binding, transactivation activity of the AD, and coac-
tivator function of CoCoA with LEF1 and β-catenin [20].
Since this p300 KIX binding domain is physically close to
the major sumoylation site (K29), we tested the effect of
sumoylation on CoCoA interaction with p300 KIX.
Because there is no obvious way to achieve a high level of
sumoylation at K29 of CoCoA, we instead mimicked the
sumoylation at K29 by fusing SUMO1 to the N-terminal
end of the N-terminal AD fragment of CoCoA (amid acids
1–190). To prevent removal of this fused SUMO by
SUMO-specific proteases, the fused SUMO1 lacked the
two tandem glycine residues found at the C-terminus of
naturally processed SUMO1. A GST-pull down assay
showed that SUMO1 fusion to the N-terminal fragment of
CoCoA (amino acids 1–190) substantially reduced the
interaction of the N-terminal AD with GST-p300 KIX (Fig.
4B). In contrast, the fusion of SUMO1 to CoCoA did not
reduce the interaction between the N-terminal fragment
of CoCoA and β-catenin. The K29R mutation had little or
no effect on the binding of CoCoA N-terminal AD to
either GST-KIX or GST-β-catenin.
As we showed previously [20], CoCoA(1–190) can func-
tion as a coactivator for LEF1 in the presence of β-catenin
(Fig. 4C, assays 1–7). This secondary coactivator activity
of CoCoA(1–190) in LEF1 mediated transcriptional acti-
vation was reduced moderately by the K29R mutation
(assays 8–12). The fact that the K29R mutation moder-
ately enhanced the activity of the Gal4 DBD-
CoCoA(1–190) fusion protein (Fig. 4A) but moderately
decreased the activity of CoCoA(1–190) as a coactivator
for LEF1 and β-catenin (Fig. 4C) suggests that Lys-29 has
a role in the coactivator function of CoCoA that is not
important for the activity of the Gal4-CoCoA fusion pro-
tein. The coactivator activity of CoCoA(1–190) was
strongly reduced by fusion of SUMO1 to CoCoA (1–190)
(assays 13–17), even though the SUMO1 fusion protein
was expressed at much higher levels than the unmodified
CoCoA(1–190) fragment. (Compare activities in assay 7
versus assays 13–14, where equivalent amounts of
CoCoA(1–190) and SUMO-CoCoA(1–190) were
expressed). Similar results were obtained with full length
CoCoA containing the K29R mutation or an N-terminal
fusion to SUMO1 (Fig. 5D and data not shown). These
results suggest that even though SUMO addition may
increase CoCoA protein synthesis or stability, sumoyla-
tion of CoCoA negatively regulates CoCoA N-terminal
transcriptional activity.
Effect of sumoylation on the function of CoCoA C-
terminal AD
When hormone-activated nuclear receptors bind to
enhancer elements associated with the genes they regu-
late, the nuclear receptors recruit p160 coactivators, which
serve as a scaffold for binding of other coactivators, such
as CBP/p300, CARM1, and CoCoA [16]. Previously we
have shown that the C-terminal AD of CoCoA contains a
strong transactivation activity which is absolutely neces-
sary for its cooperation with the p160 proteins as a coacti-
vator for nuclear receptors. Although this C-terminal
fragment of CoCoA exhibits a very powerful activity when
fused to Gal4 DBD, full length CoCoA has little or no
transactivation activity when fused to Gal4 DBD, suggest-
ing that the N-terminal region somehow inhibits the
activity of the C-terminal AD [16]. Here we show that the
N-terminal and C-terminal domains of CoCoA can phys-
ically interact (Fig. 5A), which may explain the mecha-
nism of inhibition of the C-terminal AD by the N-
terminal region. We therefore tested whether sumoylation
of the N-terminal region of CoCoA may affect the physical
interaction between the termini. Fusion of SUMO1 to the
N-terminus of CoCoA(1–190) dramatically decreased its
binding to the C-terminal AD. In contrast, the K29R
mutant of CoCoA(1–190) bound to the C-terminal AD at
wild type levels (Fig. 5A). Thus, sumoylation interferes
with the interaction between the N- and C-terminal
regions of CoCoA.BMC Molecular Biology 2008, 9:12 http://www.biomedcentral.com/1471-2199/9/12
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Effect of sumoylation on the activity of CoCoA N-terminal AD Figure 4
Effect of sumoylation on the activity of CoCoA N-terminal AD. (A) 293T cells were transfected in 24-well plates with 
GK1-Luc reporter plasmid (150 ng) and plasmids encoding Gal4 DBD or Gal4 DBD-CoCoA fusion proteins (30, 60 or 100 ng) 
as indicated. Cell extracts were assayed for luciferase activity or analyzed by immunoblot with anti-Gal4 antibody 48 h after 
transfection. Luciferase activity results shown are from a single experiment which is representative of four independent exper-
iments. (B) In vitro-translated HA-tagged CoCoA(1–190) wild type or mutant was incubated with GST, GST-p300 KIX fragment 
(left panel) or GST-β-catenin (right panel) fusion proteins bound to glutathione-Sepharose. Bound proteins were eluted and 
analyzed by immunoblot with anti-HA antibody (left panel) or autoradiography (right panel). (C) 293T cells were transfected in 
24-well plates with pGL3OT reporter plasmid (100 ng), pSG5.HA-LEF1 (1 ng), pSG5.HA-β-catenin (1 ng), and a pSG5.HA vec-
tor encoding CoCoA(1–190), CoCoA(1–190, K29R), or SUMO1-fused CoCoA(1–190) (10–175 ng) as indicated. Cell extracts 
were assayed for luciferase activity or analyzed by immunoblot with anti-HA antibody 48 h after transfection. Luciferase activity 
results shown are from a single experiment which is representative of two independent experiments. RLU, Relative light units.BMC Molecular Biology 2008, 9:12 http://www.biomedcentral.com/1471-2199/9/12
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Effect of sumoylation on the activity of CoCoA C-terminal AD Figure 5
Effect of sumoylation on the activity of CoCoA C-terminal AD. (A) In vitro-translated CoCoA(1–190) wild type, 
CoCoA(1–190, K29R), SUMO1-CoCoA(1–190) fusion protein, or SUMO1 were incubated with GST or GST-
CoCoA(470–691) fusion protein bound to glutathione-Sepharose. Bound proteins were eluted and analyzed by autoradiogra-
phy. (B) CV1 cells were transfected in 24-well plates with GK1-Luc reporter plasmid (150 ng) and plasmids encoding Gal4 
DBD or Gal4 DBD-CoCoA(470–691) (50 ng), and HA-CoCoA(1–190) wild type or K29R mutant or SUMO1-CoCoA(1–190) 
(100 or 150 ng), as indicated. Cell extracts were assayed for luciferase activity 48 h after transfection. Luciferase activity results 
shown are from a single experiment which is representative of four independent experiments. (C) 293T cells were transfected 
in 24-well plates with GK1-Luc reporter plasmid (150 ng) and plasmids encoding Gal4 DBD-CoCoA(470–691) (50 ng), p300 
(25 ng), and pSG5.HA-CoCoA(1–190) wild type or K29R mutant or SUMO1-CoCoA(1–190) (50, 100 or 150 ng) as indicated. 
Cell extracts were assayed for luciferase activity 48 h after transfection. Results shown are representative of two independent 
experiments. (D) CV-1 cells were transfected in 12-well plates with pGL3OT reporter plasmid (200 ng), pSG5.HA-LEF1 (10 
ng), pSG5.HA-β-catenin (50 ng), and a pSG5.HA vector encoding CoCoA or SUMO1-fused CoCoA, as indicated. Results 
shown are representative of three independent experiments. (E) CV-1 cells were transfected in 12-well plates with 
MMTV(ERE)-LUC reporter plasmid (200 ng), pHE0 (2 ng), pSG5.HA-GRIP1 (50 ng), and a pSG5.HA vector encoding CoCoA 
or SUMO1-fused CoCoA, as indicated. Results shown are representative of four independent experiments. For immunoblots 
CV-1 cells do not produce enough protein, so COS-7 cells were transfected with 200 or 400 ng of CoCoA expression plas-
mids. Cell extracts were subjected to immunoblot analysis with anti-HA antibody.BMC Molecular Biology 2008, 9:12 http://www.biomedcentral.com/1471-2199/9/12
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We further tested the effect of CoCoA N-C interaction on
the C-terminal transcriptional activation activity of
CoCoA. When fused to GAL4-DBD, the strong transactiva-
tion activity of CoCoA C-terminal AD (amino acids
470–691) (Fig 5B, assay 8) was strongly repressed by co-
expression of the wild type or K29R mutant of the CoCoA
N-terminal fragment (amino acids 1–190) (assays 9–12).
In contrast, the SUMO-CoCoA(1–190) fusion protein had
little or no effect on activity of the C-terminal AD (assays
13–14), consistent with its reduced ability to bind to the
C-terminal AD (Fig. 5A). These results suggest that the
strong repression by the CoCoA N-terminal fragment is
due to direct N-C interaction, which may block the ability
of the C-terminal AD to interact with and stimulate the
activity of other components of the transcription machin-
ery. Sumoylation appears to relieve the repression of the
C-terminal AD by the N-terminal domain.
Our previous studies have shown that p300 can directly
interact with both the N- and C-termini of CoCoA, and
this binding is important for the activities of both ADs
[20,22]. Here we show that while p300 enhanced the tran-
scriptional activity of CoCoA C-terminal AD (470–691),
co-expression of the wild type or K29R mutant of
CoCoA(1–190) reduced the enhancement of C-terminal
AD activity by p300 (Fig. 5C), possibly by binding to the
C-terminal AD and blocking the binding of p300. In con-
trast, the SUMO-fusion of the CoCoA N-terminus did not
block the p300 effect. The differential activities of
CoCoA(1–190) and SUMO1-CoCoA(1–190) in binding
to the CoCoA C-terminal AD (Fig. 5A), inhibiting transac-
tivation by the CoCoA C-terminal AD (Fig. 5B), and
inhibiting the stimulation of CoCoA C-terminal AD by
p300 (Fig. 5C) are consistent with our conclusions that
the N-C interaction inhibits the activity of CoCoA C-ter-
minal AD and that sumoylation at K29 enhances the activ-
ity of the C-terminal AD by preventing the N-C interaction
and thus allowing p300 to bind to the C-terminal AD and
enhance its activity.
The above results suggest that sumoylation of CoCoA
should decrease its coactivator function for LEF1/β-cat-
enin (where the N-terminal AD is required) but should
increase its coactivator activity for nuclear receptors
(where the C-terminal AD is required). We therefore
examined the effects of sumoylation on the coactivator
activity of full length CoCoA for LEF1 and estrogen recep-
tor (ER). Wild type CoCoA dramatically enhanced LEF1
reporter activity (Fig. 5D) and ER reporter activity (Fig.
5E) in the presence of β-catenin and GRIP1, respectively.
Consistent with our previous experiments (Fig. 4), fusion
of SUMO1 to CoCoA caused an increase in the level of
CoCoA protein expressed, by about 2-fold in this case,
presumably by stabilizing the protein (Fig. 5D &5E, bot-
tom panels). As expected, the coactivator activity of
CoCoA for LEF1 was decreased when CoCoA was fused
with SUMO1 (Fig. 5D), especially when assays containing
similar amounts of CoCoA and SUMO1-CoCoA are com-
pared (e.g. assays 5 & 6). This is consistent with the inhi-
bition of the N-terminal AD of CoCoA by fusion of
SUMO1. In contrast, the SUMO1-CoCoA had coactivator
activity greater than that of CoCoA, consistent with our
finding that SUMO fusion to the N-terminus of CoCoA
prevents it from binding to and inhibiting the C-terminal
AD. Taken together, these results suggest that sumoylation
is a mechanism that differentially regulates the coactivator
activity of CoCoA for LEF1 and ER.
Discussion
Sumoylation of CoCoA
Post-translational modification of proteins is a widely
used mechanism for regulation of a variety of cellular
processes. In the present study, we have shown that
CoCoA is covalently modified by SUMO1 and SUMO2 in
intact cells with PIAS1 and ARIP3 as the E3 ligases (Fig. 1,
2, 3). Lys-29 at the N-terminus of CoCoA is the major
sumoylation site, because the K29R mutant was modified
only poorly. Lys-52 may be a minor sumoylation site,
since the small amount of sumoylation of the K29R
mutant disappeared in the K29R, K52R double mutant
(Fig. 3). The K29 sumoylation site is fully conserved from
human to rat, and also present in a CoCoA homologue,
the Xenopus nuclear dot protein NDP52. Lys-52 is con-
served among CoCoA and its homologues NDP52 and
TAX1BP1, but the consensus sumoylation motif sur-
rounding K52 is only conserved in CoCoA from human to
rat.
The small relative proportion of sumoylated CoCoA that
we observed, even in the presence of an over-expressed E3
ligase (Fig. 2), suggests that only a very small fraction of
total CoCoA is sumoylated in the cell at any given time.
Whether the amount of CoCoA which is sumoylated can
be regulated by external signals, and whether the
sumoylation of CoCoA occurs only in certain sub-cellular
locations are questions which remain to be investigated.
Some lysine residues in proteins can be modified either by
sumoylation or by another type of post-translational
modification, such as acetylation, methylation, or ubiq-
uitylation. In such cases, sumoylation would prevent
other post-translational modifications of the same lysine.
In the case of IκBα [25] and Mdm2 [26], sumoylation
appears to block ubiquitylation of these proteins and pre-
vents proteasome-dependent degradation. Acetylation of
the oncogene pleomorphic adenoma gene 1 (PLAG1) by
p300 enhanced transactivation, while sumoylation on the
same lysine residue appears to have a repressive effect on
transactivation due to regulation of subnuclear localiza-
tion [27]. Other post-translational modifications haveBMC Molecular Biology 2008, 9:12 http://www.biomedcentral.com/1471-2199/9/12
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also been shown to be involved in regulation of protein
sumoylation. Phosphorylation of MEF2C, a member of
the myocyte enhance factor 2 family, has been shown to
enhance SUMO-conjugation at a site in close proximity to
the phosphorylation site [28]. The human CoCoA was
recently found to be an in vitro substrate of p42 MAPK and
of CDK2/Cyclin E with predicted phosphorylation sites in
both the N- and C-terminal activation domains [29].
However, we did not find any known phosphorylation-
dependent sumoylation motifs near the major K29
sumoylation site or the possible minor K52 sumoylation
site in CoCoA. Further studies on the various post-transla-
tional modifications of CoCoA, their functional interac-
tions, and their biological roles are needed to delineate
the complex regulation of CoCoA.
Sumoylation regulates CoCoA AD activity
Sumoylation is involved in the regulation of many cellu-
lar processes. SUMO-modification of transcription factors
is frequently connected to transcriptional repression. In
some cases the transcriptional repression is due to
sumoylation-induced alteration in cellular localization of
the target proteins. For example, PIASy stimulation of
LEF1 sumoylation in the Wnt signaling pathway results in
sequestering of LEF1 to the PML nuclear bodies, which
causes inhibition of LEF1-transcription [12]. Sumoylation
has also been shown to regulate protein-protein interac-
tions, resulting in transcriptional repression. For instance,
sumoylation of p300 and the ETS domain transcription
factor Elk-1 leads to transcriptional repression through
recruitment of HDAC6 [30] and HDAC2 [31], respec-
tively. SUMO-modification of several transcription fac-
tors, including androgen receptor [32], glucocorticoid
receptor [33], ETS-1 [34], Pax3 [35], and Smad4 [36], has
also been shown to recruit the transcriptional corepressor
Daxx. However, exceptions have also been found to the
generally negative effect of sumoylation in transcriptional
regulation. Sumoylation of GRIP1 has been shown to pro-
mote its interaction with nuclear receptors and enhance
its coactivator function. Mutation of the SUMO-modifica-
tion site attenuated the ability of GRIP1 to enhance
androgen receptor-dependent transcription [24].
CoCoA contains two known transcriptional ADs. The N-
terminal AD of CoCoA is required for the coactivator
function of CoCoA in the LEF1/β-catenin-mediated Wnt
signaling pathway. The C-terminal AD of CoCoA is
required for the coactivator function of CoCoA with
nuclear receptors. The utilization of different ADs by
CoCoA in different coactivator complexes may be regu-
lated through post translational modifications. Here we
fused SUMO1 to the N-terminal end of CoCoA to mimic
the natural sumoylation event at K29. While the N-termi-
nal fusion does not necessarily replicate the exact pheno-
type of natural sumoylation, it has been used as a model
for the functional effects of sumoylation. Our results with
this SUMO fusion model suggest that sumoylation of
CoCoA regulates the differential use of the ADs. Mimick-
ing sumoylation by fusing SUMO1 to CoCoA or
CoCoA(1–190) attenuated the N-terminal AD activity
and the coactivator activity in β-catenin/LEF1-mediated
transcriptional activation (Fig. 4 &5D). This reduced sec-
ondary coactivator activity may be due to the sumoyla-
tion-induced reduction in the interaction of the N-
terminal AD with p300 (Fig. 4B), which contributes to the
N-terminal AD activity in the β-catenin/LEF1 coactivator
complex [20].
On the other hand, the regulation of the C-terminal AD by
sumoylation appears to be more complex. The C-terminal
AD is required for CoCoA coactivator function with
nuclear receptors. When CoCoA functions as a coactivator
for nuclear receptors, p300 has been shown to interact
with and contribute to transcriptional activation by the C-
terminal AD of CoCoA [22]. Since sumoylation of CoCoA
N-terminus reduces the interaction of CoCoA N-terminus
with p300 (Fig. 4B), this may increase the availability of
p300 for contributing to the activity of the CoCoA C-ter-
minal AD. In addition, we demonstrated an interaction
between N- and C-termini of CoCoA (Fig. 5A) and
showed that this interaction attenuated the activity of the
C-terminal AD (Fig. 5B), apparently by preventing interac-
tion of the C-terminal AD with p300 (Fig. 5C). Fusion of
SUMO1 to the CoCoA N-terminal fragment (mimicking
sumoylation) disrupted the N-C interaction (Fig. 5A) and
prevented the negative regulation of the C-terminal AD by
the N-terminus (Fig. 5B–C). Furthermore, as predicted
from the above results, fusion of SUMO1 to full length
CoCoA enhanced its coactivator activity with ER and
GRIP1, where the CoCoA C-terminal AD is required (Fig.
5E). While regulation of protein-protein interaction and
transcriptional repression by sumoylation have been
widely demonstrated, the use of sumoylation for differen-
tial utilization of transcriptional ADs in a single protein is
a novel concept.
How can sumoylation of such a small fraction of total cel-
lular CoCoA have any effect on the activity of CoCoA?
One possibility is that certain external signals might result
in a large increase in the fraction of total cellular CoCoA
that is sumoylated. We would expect an increase in
sumoylation of CoCoA to favor nuclear receptor function
at the expense of LEF1/β-catenin-mediated transcription,
and this was borne out by our results (Fig. 5D &5E).
Another possibility is that CoCoA is only sumoylated
under specific circumstances where the activity of the C-
terminal AD is required. The fact that over-expression of
E3 ligases enhances the sumoylation of CoCoA (Fig. 2)
suggests that the E3 ligases are limiting and that sumoyla-
tion of CoCoA may be regulated by controlling access ofBMC Molecular Biology 2008, 9:12 http://www.biomedcentral.com/1471-2199/9/12
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the E3 ligases to CoCoA. Some of the SUMO E3 ligases
have been shown to function as coactivators for nuclear
receptors [24]. Therefore, we propose that sumoylation of
CoCoA may occur when CoCoA and PIAS1 or ARIP3 are
recruited by hormone-activated nuclear receptors to a spe-
cific target gene promoter. The juxtaposition of CoCoA
with an E3 ligase in the coactivator complex could result
in an efficient localized sumoylation of CoCoA at K29.
This sumoylation would prevent intra-molecular binding
between the N- and C-termini of CoCoA and thereby
relieve repression of the C-terminal AD of CoCoA by the
N-terminal AD. Perhaps only a transient disruption of the
N-C interaction is required to allow the C-terminal AD of
CoCoA to carry out its coactivator function.
Conclusion
The studies shown here demonstrated the potential role of
SUMO1 modification in regulating the transcriptional
activity of CoCoA. The transcriptional coactivator CoCoA
utilizes two different ADs to function in various regulatory
contexts on different promoters. The binding of CoCoA to
p160 coactivators (in nuclear receptor-mediated gene reg-
ulation) versus β-catenin (in LEF1-mediated gene regula-
tion) appears to dictate which of the CoCoA ADs is used
for transcriptional activation. Our results suggest that
sumoylation of CoCoA differentially regulates the activi-
ties of the ADs by attenuating the N-terminal AD activity,
inhibiting the interaction between the CoCoA N- and C-
termini, and thus enhancing the activity of the C-terminal
AD. Our results also suggest that CoCoA sumoylation
therefore enhances the coactivator activity of CoCoA with
nuclear receptors while it inhibits the coactivator function
of CoCoA with β-catenin and LEF1.
Methods
Plasmids
pSG5.HA-CoCoA, pSG5.HA-CoCoA(1–190), pSG5.HA-
CoCoA(1–500), pSG5.HA-CoCoA(150–500), pSG5.HA-
CoCoA(470–691), pGEX-5X1.CoCoA(470–691),
pM.CoCoA(1–149), pM.CoCoA(1–190), pSG5.HA-
GRIP1, pHE0, and MMTV(ERE)-LUC were described pre-
viously [16,22]. pM.CoCoA(1–190, K29R), pSG5.HA-
CoCoA(K29R), pSG5.HA-CoCoA(K52R) and pSG5.HA-
CoCoA(K29R, K52R) were made using the Quick Change
Site-Directed Mutagenesis kit (Stratagene) following the
manufacturer's instructions. Plasmids expressing EGFP-
SUMO1, Myc-SUMO2, PIAS1 and ARIP3 were kind gifts
from Dr. David Ann (City of Hope, Duarte, California)
and Jorma Palvimo (University of Helsinki, Finland).
SUMO1 fusion protein was constructed by inserting a
PCR amplified CoCoA full length, (1–190) or (1–190,
K29R) into the XhoI/BglII site of a pSG5HA.SUMO1
mutant which lacks the two tandem glycines at the C-ter-
minus of processed SUMO1.
Cell culture and transfections
CV-1, 293T and COS-7 cells were maintained in Dul-
becco's modified Eagle's medium (DMEM) with 10% fetal
bovine serum and penicillin and streptomycin. For
reporter gene assays, CV-1 and 293T cells were transiently
transfected in 12-well or 24-well plates and assayed for
luciferase activity as described previously [16]. Mean and
standard deviation of triplicate points are shown for one
representative transfection experiment which is represent-
ative of multiple independent experiments.
Protein-protein interaction assay
GST pull-down assays were performed as described previ-
ously [16] using either in vitro translated protein or cell
extracts from COS-7 cells transiently transfected with the
indicated plasmids. The bound proteins were eluted from
the beads and analyzed by immunoblot with anti-HA
antibody (Roche Applied Science).
In vivo and in vitro sumoylation assay
293T or COS-7 cells were transfected with the indicated
plasmids encoding proteins with an HA-tag. Cell extracts
were collected in the presence of 20 mM N-ethylmaleim-
ide 40 h post-transfection. Immunoblots were performed
with anti-HA antibody. The in vitro sumoylation assay
was performed with a SUMOylation kit (BIOMOL Inter-
national, LP) using in vitro translated 35S-labeled protein
as substrates.
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